Seaport Therapeutics Secures $15M ARPA-H Grant to Develop Gut Lymphatic Therapy — Seaport Therapeutics, Inc.

Event summary

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences received up to $15 million from ARPA-H to advance GlyphCele™, an oral therapeutic targeting gut lymphatic dysfunction.
GlyphCele™ is designed to restore gut lymphatic function, addressing metabolic disease and pancreatic cancer by reducing lymphatic leakage and inflammation.
The award supports the development of an investigational Glyphed oral prodrug of celecoxib, aiming to establish a disease-modifying approach in metabolic disease and pancreatic cancer.
The program is part of ARPA-H’s GLIDE initiative, focusing on lymphatic-targeted therapies for chronic conditions.

The big picture

Seaport Therapeutics’ $15 million ARPA-H grant underscores the growing interest in lymphatic-targeted therapies, a niche area with limited approved treatments. The collaboration with Monash Institute of Pharmaceutical Sciences highlights the strategic shift toward addressing underlying disease biology rather than symptom management, potentially transforming treatment paradigms in metabolic disease and pancreatic cancer. The success of GlyphCele™ could validate the Glyph platform’s broader applicability, positioning Seaport as a key player in lymphatic-focused drug development.

What we're watching

Clinical Progress: The pace at which GlyphCele™ advances through preclinical and clinical studies will determine its potential market impact.
Platform Expansion: Whether Seaport can leverage the Glyph platform beyond neuropsychiatric indications into metabolic disease and oncology.
Regulatory Pathway: How ARPA-H’s GLIDE program influences the regulatory approval process for lymphatic-targeted therapies.